Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being

por Brod, Meryl, Pohlman, Betsy, Wolden, Michael, Christensen, Torsten
Publicado 2012

Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden

por Steen Carlsson, Katarina, Faurby, Mads, Nilsson, Kristoffer, Wolden, Michael Lyng
Publicado 2023

Economic burden of atherosclerotic cardiovascular disease: a matched case–control study in more than 450,000 Swedish individuals

por Steen Carlsson, Katarina, Nilsson, Kristoffer, Wolden, Michael Lyng, Faurby, Mads
Publicado 2023

Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data

por Kaku, Kohei, Wolden, Michael Lyng, Hyllested-Winge, Jacob, Nørtoft, Emil
Publicado 2017

Diabetes management and daily functioning burden of non‐severe hypoglycemia in Japanese people treated with insulin

por Ohashi, Yasuo, Wolden, Michael L, Hyllested‐Winge, Jacob, Brod, Meryl
Publicado 2017

Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy

por Langer, Jakob, Wolden, Michael L., Shimoda, Seiya, Sato, Miki, Araki, Eiichi
Publicado 2019

Cost of Self-Monitoring of Blood Glucose in Canada among Patients on an Insulin Regimen for Diabetes

por Yeaw, Jason, Lee, Won Chan, Wolden, Michael Lyng, Christensen, Torsten, Groleau, Danielle
Publicado 2012

Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes

por Sreenan, Seamus, Andersen, Marc, Thorsted, Brian Larsen, Wolden, Michael L., Evans, Marc
Publicado 2014

Healthcare resource implications of hypoglycemia-related hospital admissions and inpatient hypoglycemia: retrospective record-linked cohort studies in England

por McEwan, Philip, Larsen Thorsted, Brian, Wolden, Michael, Jacobsen, Judith, Evans, Marc
Publicado 2015

Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people

por Khunti, Kamlesh, Wolden, Michael L., Thorsted, Brian Larsen, Andersen, Marc, Davies, Melanie J.
Publicado 2013

Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes

por Paul, Sanjoy K, Klein, Kerenaftali, Thorsted, Brian L, Wolden, Michael L, Khunti, Kamlesh
Publicado 2015

Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Co...

por Melzer Cohen, Cheli, Thorsted, Brian Larsen, Wolden, Michael Lyng, Chodick, Gabriel, Karasik, Avraham
Publicado 2017

Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control

por Tentolouris, Nikolaos, Knudsen, Søren T., Lapolla, Annunziata, Wolden, Michael Lyng, Haldrup, Steffen, Schultes, Bernd
Publicado 2019

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)

por Desouza, Cyrus, Kirk, Andreas R, Mangla, Kamal K, Wolden, Michael L, Lingvay, Ildiko
Publicado 2020

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study

por Lingvay, Ildiko, Kirk, Andreas R., Lophaven, Søren, Wolden, Michael L., Shubrook, Jay H.
Publicado 2021

Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study

por Aroda, Vanita R., Faurby, Mads, Lophaven, Søren, Noone, Josh, Wolden, Michael Lyng, Lingvay, Ildiko
Publicado 2021

A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada

por Qureshy, Kamran, Ross Kirk, Andreas, Lyng Wolden, Michael, Abbas Mohseni Zonoozi, Amir, Liu, Aiden
Publicado 2022

A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin‐naïve patients with type 2 diabetes

por Tibaldi, Joseph, Hadley‐Brown, Martin, Liebl, Andreas, Haldrup, Steffen, Sandberg, Viktor, Wolden, Michael L., Rodbard, Helena W.
Publicado 2019

A European, multicentre, retrospective, non‐interventional study (EU‐TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or ty...

por Siegmund, Thorsten, Tentolouris, Nikolaos, Knudsen, Søren T., Lapolla, Annunziata, Prager, Rudolf, Phan, Tra‐Mi, Wolden, Michael L., Schultes, Bernd
Publicado 2017

Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study

por Fadini, Gian Paolo, Feher, Michael, Hansen, Troels Krarup, de Valk, Harold W, Koefoed, Mette Marie, Wolden, Michael, Zimmermann, Esther, Jendle, Johan
Publicado 2019